Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)).
Novartis bags new breakthrough status for Kisqali in breast cancer

In the study, giving Kisqali (ribociclib) in combination with tamoxifen or an aromatase inhibitor as initial endocrine-based therapy for women in this group significantly prolonged progression-free survival (PFS) compared
NICE backs two advanced breast cancer drugs after price cuts

The draft guidance for palbociclib and ribociclib means that an estimated 8, 000 women will be eligible to receive the new drugs, which in trials have been shown to slow the ... By postponing disease progression, palbociclib and ribociclib may reduce the
Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

In the study, women taking Kisqali (ribociclib) on top of hormonal therapy as a first-line intervention had a longer progression-free survival (PFS) than those on hormonal therapy alone, said
Prospects for Lilly’s Verzenio hit by botched lung cancer trial

palbociclib) and Novartis with recently-launched Kisqali (ribociclib), although it reckons Verzenio can still lead in breast cancer after picking up an early approval from the FDA towards the end of

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....